Por medio del Acuerdo de , la Comisión de Regulación en Salud – CRES-, introdujo ajustes al Acuerdo , por medio del cual se. acuerdo de cres pdf. Quote. Postby Just» Tue Aug 28, am. Looking for acuerdo de cres pdf. Will be grateful for any help! Top. P P 11 1 P(|racu|ra |loslalo) 15 rd de oase lao|ela o cápsu|a. P Z0 1 0u|r|ra d|c|o(r|d(alo rd/2 rL so|uc|ór |rveclao|e. P 10 1 0u|r|ra.
|Published (Last):||5 June 2013|
|PDF File Size:||11.95 Mb|
|ePub File Size:||17.40 Mb|
|Price:||Free* [*Free Regsitration Required]|
Eficacia del tratamiento hipolipemiante en una muestra de pacientes de Colombia.
Because a lack LDL-C control occurred in patients with two or more of the following variables: Arterioscler Thromb Vasc Biol.
Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: Models of binary logistic regression were applied using the LDL-C and triglyceride levels as the dependent variable, and variables that were significantly-associated with the dependent variable were acuerxo covariables in the bivariate analysis.
Manuscript received on 14 May Any incomplete record was replaced by the complete record of another randomized patient from the same city and of the same sex and age group.
There was a problem providing the content you requested
The mean doses that were used were: Colombia has adopted an essential drugs list into the Plan Obligatorio de Salud Mandatory Health Plan, POS ; initially it included three generic agents for dyslipidemia management: Am J Geriatr Pharmacother. Effects of Quality Improvement Strategies for type 2 diabetes on glycemic control. Quality and effectiveness of diabetes care for a group of patients in Colombia. Unfortunately, dyslipidemia treatment meets the three conditions that are associated with poor adherence: A difference was found between the initial and final LDL-C levels despite the statistically-significant reduction percentages, which are lower than those reported for lovastatin acuefdo other studies 4.
Rev Salud Publica Bogota. However, despite the guidelines and the evidence of treatment benefits and safety, numerous studies have shown that a small proportion of dyslipidemic patients regularly use lipid-lowering drugs, and an even smaller percentage of people treated have serum cholesterol levels within the range recommended by international protocols Controlled versus uncontrolled dyslipidemic patients For risk group 1, the average dose of lovastatin was higher in the controlled patients than in the uncontrolled 74 vs.
acuerdo 029 de 2011 cres pdf
Diario Oficial de Colombia. Issues and evidence for the management of dyslipidaemia in primary care.
Among those at moderate risk, A significant association was found between the rate of total-C control and the following variables: The goal of the ATP Acyerdo is for the Framingham score to quantify each patient’s “absolute risk of coronary heart disease over 10 years” during routine medical consultation 7, 9.
This can be correlated with a lack of knowledge on the part of many physicians around what is a desirable goal based on the patient’s risk and what drug and dose crws be prescribed to reach it The use of lipid-lowering drugs was examined, and the number of patients receiving monotherapy was as follows: J Manag Care Pharm.
Normatividad CRES – Acuerdo de Anexo 1 –
To access other dyslipidemia control medications, the prescribing physician makes a special request through each Empresa Promotora de Salud health services provider, EPS to the Scientific Technical Committee CTC 11, These cities acuwrdo selected for convenience because they had relevant and reliable databases available.
Information on sociodemographic and anthropometric characteristics, risk factors, and pharmacological and laboratory variables were obtained from medical records. Fitzner K, Heckinger E.
For risk group 1, the average dose of lovastatin was higher in the controlled patients than in the uncontrolled 74 vs. According to the results of the present study, the prevalent characteristics of patients in the high cardiovascular risk group with uncontrolled dyslipidemia are two or more of following variables: Reduction of global cardiovascular risk with nutritional versus nutritional plus physical activity intervention in Colombian adults.
Of the 25 patients in risk group 3, Strategies for optimizing treatment outcomes. Statin treatment for primary prevention of vascular disease: On average, there was a 4. Inatorvastatin was added to the list From a total of 8 patients in crs cities, a random sample of was stratified according to dyslipidemia.
Most patients in the present study had other risk factors that increased the difficulty of dyslipidemia management and control, especially for asymptomatic diseases, such as hypertension, diabetes, and hypothyroidism; and the use of additional medications for each of these problems results in patients with polypharmacy, as reported by another study Additionally, the presence of comorbidities, such as diabetes mellitus, which contribute to cardiovascular auerdo, should be evaluated for treatment crew the drug of choice and at the appropriate dose Lipid concentrations and the use of lipid lowering drugs: Eur J Cardiovasc Prev Rehabil.
Also of note is that the entire sample of patients received generic drugs.
acuerdo de cres pdf – PDF Files
Under these circumstances, strategies aimed at identifying individuals with dyslipidemia and implementing primary and secondary CVD preventive measures have become health priorities.
The quality of the patient records was reviewed by two physicians. In this study the controlled patients received doses of lovastatin that were significantly higher than those administered to the uncontrolled patients, but all patients received DDDs lower than the recommended values, as has been reported elsewhere Definition of effectiveness The effectiveness of lipid-lowering therapies was established based on the following groups, defined according to the ATP III goal set and whether it was achieved or not: In the patients comprising risk group 1, Conversely, it is recommended that insurance companies monitor treatment effectiveness, and even adjust the medication in question, or recommend that the clinician do so There was no statistical significance with the following variables: Therapy adherence was determined by the degree to which the patient complied with the recommendations recorded by the doctor in the medical record.
In patients with high cardiovascular risk,